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Abstract 53 
Mechanisms underlying the development of Idiopathic Dilated Cardiomyopathy (DCM) 54 
remain poorly understood. Using transcription factor expression profiling, we identified 55 
estrogen-related receptor beta (ESRRβ), a member of the nuclear receptor family of 56 
transcription factors, as highly expressed in murine hearts and other highly oxidative 57 
striated muscle beds. Mice bearing cardiac-specific deletion of ESRRβ (MHC-ERRB KO) 58 
develop dilated cardiomyopathy and sudden death at approximately 10 months of age. 59 
Isolated adult cardiomyocytes from the MHC-ERRB KO mice showed an increase in 60 
calcium sensitivity and impaired cardiomyocyte contractility, which preceded 61 
echocardiographic cardiac remodeling and dysfunction by several months. Histological 62 
analyses of myocardial biopsies from patients with various cardiomyopathies revealed 63 
that ESRRβ protein is absent from the nucleus of cardiomyocytes from patients with 64 
DCM, but not other forms of cardiomyopathy (ischemic, hypertrophic and 65 
arrhythmogenic right ventricular cardiomyopathy). Taken together these observations 66 
suggest that ESRRβ is a critical component in the onset of dilated cardiomyopathy by 67 
affecting contractility and calcium balance. 68 
  69 
New and Noteworthy 70 
ESRRβ is highly expressed in the heart and cardiac specific deletion results in the 71 
development of a dilated cardiomyopathy (DCM). ESRRβ is mislocalized in human 72 
myocardium samples with DCM, suggesting a possible role for ESRRβ in the 73 
pathogenesis of DCM in humans. 74 
  75 
Introduction 76 
Heart failure is a major health concern and a leading cause of death in the 77 
developing world. Idiopathic dilated cardiomyopathy (DCM) occurs in the absence of 78 
epicardial or other known cardiac diseases. Its etiology is often genetic, most frequently 79 
involving mutations in TTN, the gene encoding for the large sarcomeric protein titin(19, 80 
20).  However, the molecular triggers that lead to the development of DCM, often later in 81 
adult life, remain poorly understood. The heart is a highly metabolic organ, one third of 82 
which is composed of mitochondria, and consuming up to 20% of systemic oxygen 83 
consumption at rest. Mutations in various components of mitochondrial function lead to 84 
dilated cardiomyopathy(21, 36), underscoring the importance of oxidative metabolism in 85 
the heart.  Some pathways that negatively affect metabolism have also been suggested 86 
as being contributors to the development of more common forms of cardiomyopathy (21, 87 
32), and human late-stage heart failure reveals defects in oxidative metabolism(11, 24), 88 
and is often considered to be “energy-starved” (22, 31, 33). 89 
In order to identify novel transcriptional regulators of cardiac and oxidative 90 
metabolism, we performed a gene expression screen in various oxidative striated 91 
muscles beds and cells. To accomplish this, we took advantage of the PGC-1α 92 
transcriptional coactivator as a potent regulator of oxidative metabolism. PGC-1α was 93 
first identified in a yeast two-hybrid screen looking for factors that interact with the 94 
PPARγ transcription factor in brown adipocyte cells(37), and has since emerged as a 95 
critical regulator of oxidative metabolism and mitochondrial function (27, 40, 44). Ectopic 96 
overexpression of PGC-1α in cardiomyocytes in both cell culture and in vivo markedly 97 
increases oxygen consumption capacity and fatty acid oxidation with a concomitant 98 
decrease in glucose oxidation(25, 47). Conversely PGC-1α null mice exhibit impaired 99 
bioenergetics in cardiomyocytes, associated with decreased ATP generation(3, 26). 100 
Moreover, under conditions of stress such as aortic constriction, PGC-1α null hearts are 101 
more susceptible to heart failure(4). PGC-1α does not bind to DNA directly, and requires 102 
the induction and subsequent activation of transcription factors to mediate its effect on 103 
gene transcription. 104 
Here we identify estrogen-related receptor beta (ESRRβ) as being highly 105 
expressed in conditions of high oxidative metabolic capacity. We show that mice lacking 106 
cardiac ESRRβ develop DCM in mid-life, preceded by pronounced defects in calcium 107 
handling and cellular contractility. Lastly, we show that ESRRβ nuclear expression is lost 108 
in human DCM suggesting a role in the pathogenesis of human DCM. 109 
 110 
Methods and Materials 111 
Human studies. All procedures were approved by the University of Pennsylvania and 112 
Beth Israel Deaconess Medical Center Institutional Review Boards (IRB).  113 
Animal studies. All animal experiments were performed according to procedures 114 
approved by the Beth Israel Deaconess Medical Center’s Institutional Animal Care and 115 
Use Committee. Mice floxed for exon 2 of ESRRβ (ESRRBflox/flox) as previously 116 
described(9),and mice expressing Cre recombinase under the control of the alpha-117 
myosin heavy chain promoter (α-MHC-Cre+/-) as previously described (1, 4, 35), were 118 
obtained from (Jackson Labs Stock # 007674 and 018972 respectively) were crossed to 119 
generate a cardiac-specific ESRRβ KO (MHC-ERRB KO) (ESRRBflox/flox/α-MHC-Cre+/-) 120 
animals. Muscle-specific PGC-1α transgenic mice were previously described(29). All 121 
animals were maintained on C57BL/6 background. Mice were maintained on standard 122 
rodent chow with a 12-h light and dark cycles. Echocardiogrpahy were performed on 123 
non-anesthetized mice using a Vivid FiVe ECHO system (GE Medical Systems), M-124 
mode recordings at the mid-ventricle region of the heart were taken. Unless otherwise 125 
stated animals were taken at 4 months, 6 months and 9 months.  126 
Gene expression studies. Total RNA was isolated from tissues and cells using Trizol 127 
(Invitorgen) following manufacturer’s instructions and subjected to reverse transcription 128 
using High Capacity Reverse Transcription (Invitrogen). Quantitative real-time PCR was 129 
performed on cDNA using the intercalating fluorescent dye SYBR green (BioRad) with 130 
gene specific primers using a CFX 384 Touch real-time PCR machine (BioRad). Relative 131 
expression was determined using the Comparative cycle threshold method (2-∆∆Ct) with 132 
36B4, HPRT and TBP used as housekeeping genes. For human samples used for gene 133 
expression studies, whole human hearts were procured from two separate patient 134 
groups: patients with end-stage heart failure who received heart transplants and hearts 135 
from brain dead organ donors. The failing hearts (dilated CM n=13 and ischemic CM 136 
n=13) came from patients undergoing transplants at the University of Pennsylvania.  137 
Hearts from brain-dead organ donors were made available through the Gift of Life Donor 138 
Program (Philadelphia, PA) and the selected cases had no history of heart failure or 139 
evidence of significant myocardial pathology (non-failing controls n=13). Tissue from 140 
age-matched individuals with no pathological or clinical evidence of heart disease were 141 
subjected to the same protocol and used as controls. 142 
Complex IV and Citrate synthase enzymatic activity. Heart samples were snap frozen 143 
with liquid nitrogen until ready to process. Complex IV activity was measured by 144 
oxidation of cytochrome c as previously described (6, 43).  Citrate synthase activity was 145 
measured as previously described (42).  146 
Cardiomyocyte calcium Imaging and contractility. Adult murine ventricular 147 
cardiomyocytes from wild type and transgenic mice were isolated as previously 148 
described(16) and loaded with 0.25μg Fura2-AM for subsequent calcium transient 149 
analysis using the MMSYS IonOptix imaging system.  Isolated cardiomyocytes were 150 
stimulated with 15V at a frequency of 5Hz to induce uniform cell contraction at 37 °C.  151 
Contractility measurements were calculated using sarcomere shortening distances from 152 
real-time phase-contrast images.  Intracellular calcium concentrations were calculated 153 
from the ratio of bound to unbound Fura2-AM.  These measurements were used to 154 
determine contractile and calcium transients depicting the cell’s overall contractility or 155 
the flux of calcium across the cell membrane.  Both contractility measurements and 156 
calcium transients were recorded for 5-10 minutes, at which point each curve was 157 
averaged to generate a representative contractile or calcium transient plot for each cell 158 
recorded.  These plots were then analyzed using a monotransient data analysis 159 
algorithm to generate surrogate parameters for systolic and diastolic function for that 160 
cell. 161 
Immunofluorescence staining of human heart samples. De-identified samples came from 162 
native hearts of patients who had undergone cardiac transplantation due to end-stage 163 
heart failure. Transmural sections of right and left ventricles from patients with 164 
hypertrophic (n=3), with dilated (n=4) and with ischemic (n=3) cardiomyopathies were 165 
analyzed. The second set of samples came from  patients who had died suddenly and 166 
diagnosed with arrhythmogenic right ventricular (n=3) cardiomyopathy at postmortem 167 
examination. Tissue from age-matched individuals with no pathological or clinical 168 
evidence of heart disease were subjected to the same protocol and used as controls 169 
(n=3). Samples were processed in formalin and subjected to paraffin embedding. In 170 
preparation for immunofluorescence microscopy, deparaffinized, rehydrated slide-171 
mounted sections were heated in citrate buffer (10mmol/l, pH 6.0) to enhance specific 172 
immunostaining.  After being cooled to room temperature, the tissue sections were 173 
simultaneously permeabilized and blocked by incubating them in phosphate-buffered 174 
saline (PBS) containing 1% Triton X-100, 3% normal goat serum and 1% bovine serum 175 
albumin.  The sections were then incubated first with a primary antibody and then with 176 
indocarbocyanine-conjugated goat anti-rabbit IgG.  Primary antibodies 177 
included polyclonal rabbit anti-ERR1 (Thermo Fisher), polyclonal rabbit anti-ERRB 178 
(Thermo Fisher) and polyclonal rabbit N-Cadherin (Sigma).  Immunostained 179 
preparations were analyzed by confocal microscopy (Sarastro Model 2000, Molecular 180 
Dynamics) as previously described(41). 181 
Statistical analysis. The data are presented as means ± standard error of the mean 182 
(SEM). Statistical analysis was performed with Student’s t test for in vitro experiments 183 
and ANOVAs for all in vivo experiments. Univariate statistics were performed on 184 
Contraction and calcium variables to assess distribution of values. For each time point, 185 
the effect of ERRB KO status on each response variable was modeled using generalized 186 
estimating equations, accounting for the distribution of each response variable as well as 187 
nesting of cell samples within the same mouse. For comparisons of presence or 188 
absence of nuclear ESRRB on human biopsies, the nonparametric Chi-Square test of 189 
association was used.  P values of less than 0.05 were considered statistically significant. 190 
 191 
Results 192 
Identification of ESRRβ in a screen for transcription factors highly expressed in 193 
oxidative muscle.  194 
We sought to identify transcription factors that were differentially expressed in striated 195 
muscle beds of high versus low oxidative capacity. We utilized a high throughput screen 196 
in which the expression of ~2000 known or putative transcription factors are screened by 197 
qPCR(17, 18, 38). We compared the expression of the TFs in murine muscle or cells in 198 
4 contexts:  1.) slow twitch soleus muscle versus fast twitch quadriceps muscle, 2.) 199 
quadriceps vs cardiac muscle, 3.) PGC-1α overexpression in cultured myotubes versus 200 
GFP-only expression, and 4.) transgenic PGC-1α overexpression in quadriceps versus 201 
littermate control. As shown in Figure 1A, five TFs were found in all four cases to be 202 
more highly expressed in the more oxidative tissue or cells. The five TFs included PGC-203 
1α itself, as well as PPARα, a nuclear receptor well-known to control programs of fatty 204 
acid oxidation in these contexts (8, 28). The most highly differentially expressed TF after 205 
PGC-1α was ESRRβ (Figure 1B). ESRRβ is a member of the three-member ESRR 206 
family of transcription factors, named for their primary homology to the estrogen receptor 207 
(ESR), though importantly estrogen likely does not bind to members of the ESRR family. 208 
ESRRα and ESRRγ have been studied extensively as drivers of oxidative metabolism in 209 
muscle and other tissues (15, 46), but little is known of the role of ESRRβ in muscle 210 
tissues. qPCR analysis of RNA isolated from various tissues revealed that ESRRβ is 211 
most highly expressed in the heart, followed by muscle, kidney, testes, brain, and 212 
stomach, all of which are highly oxidative tissues (Figure 1C). 213 
 214 
Cardiac-Specific Deletion of ESRRβ leads to profound adult-onset dilated 215 
cardiomyopathy.  216 
ESRRβ is most highly expressed in the heart, yet its role in cardiac physiology is 217 
unknown. To determine the role of ESRRβ in the heart we generated a cardiac-specific 218 
knockout of ESRRβ using the alpha-myosin heavy chain (α-MHC) promoter driving the 219 
expression of Cre recombinase and ESRRβ floxed mice to obtain MHC-ERRB KO 220 
animals. The MHC-ERRB KO animals had a 95% reduction in ESRRβ in the heart, with 221 
no loss of ESRRβ expression in skeletal muscle and kidney (Figure 1D). The significant 222 
deletion of ESRRβ with the α-MHC promoter suggests that in the heart ESRRβ is 223 
primarily expressed within cardiomyocytes and not other cells. The MHC-ERRB KO mice 224 
were born at Mendelian ratios with no overt phenotype at birth. However, the MHC-225 
ERR β KO had poor survival rates after 9 to 10 months of age as quantified by Kaplan-226 
Meier survival curve analysis (Figure 2A). Gross analysis of the hearts from these 227 
animals at 9 months revealed a significantly enlarged heart (Figure 2B). Gravimetric 228 
analysis of heart parameters revealed a significant increase in heart weight to body 229 
weight (Figure 2C) as well as heart weight to tibial length (Figure 2D). qPCR analysis of 230 
ventricular RNA revealed an increase in the expression of ANF, BNP and β-MHC, and a 231 
trend towards a decrease in α-MHC (Figure 2E). These data indicate a heart failure gene 232 
signature in the hearts of the MHC-ERRB KO. Masson’s Trichrome staining of the left 233 
ventricle revealed a significant increase in fibrosis (Figure 2F). This increase in fibrosis 234 
was confirmed by qPCR analysis revealing a significant increase in collagen and other 235 
fibrotic markers (Figure 2G).  236 
We next sought to evaluate cardiac function in the MHC-ERRB KO by non-237 
invasive echocardiography (ECHO). Two dimensional M-mode analysis of the ECHOs 238 
revealed a significant dilated cardiomyopathy (Figure 3A) associated with a decrease in 239 
anterior wall thickness (AW) (Figure 3B), significantly increased left ventricular end 240 
systolic diameter (LVESD) (Figure 3C) and left ventricular end diastolic diameter 241 
(LVEDD) (Figure 3D), and a 60% decrease in fractional shortening (FS) (Figure 3E). 242 
This decrease in cardiac function is associated with a decrease in OXPHOS genes and 243 
FAO genes as revealed by qPCR analysis (Figure 3F and 3G), and a small but not 244 
statistically significant decline in complex IV activity and citrate synthase activity (Figure 245 
3H and 3I). Interestingly, no evidence of cardiac dysfunction on echocardiography was 246 
seen at earlier time points in life, including 4 and 6 months (Figure 4A-H). We did not 247 
observe any changes in expression of the other ESRR family members (Figure 4I) or 248 
genes involved in OXPHOS (Figure 4J), although at 6 months the expression of ANF 249 
and BNP did start to increase (Figure 4K). Taken together these data demonstrate that 250 
loss of ESRRβ result in the development of pronounced dilated cardiomyopathy during 251 
mid-to-late murine life. 252 
 253 
Cardiomyocytes from MHC-ERRB KO mice exhibit impaired contractility and 254 
calcium handling.  255 
We next sought to determine whether the loss of ESRRβ had a cell autonomous effect 256 
on cardiomyocyte function. Ventricular cardiomyocytes were isolated from MHC ERRB 257 
KO mice at 4, 6 and 9 months of age and compared to wild type, age-matched 258 
littermates (Figure 5A-C).  Length measurements of the isolated cardiomyocytes 259 
revealed a significant increase in sarcomere length only after 9 months (Figure 5C), 260 
consistent with the timing of echocardiographic phenotype of left ventricular dilation 261 
(Figure 3).  However, this structural defect was preceded at 6 months by contractile 262 
dysfunction evidenced by a decrease in both contractile distance (sarcomere shortening, 263 
Figure 5D-F) and speed of contraction (Figure 5G-I), both of which persisted at the 9-264 
month time point. Evidence of cell-autonomous contractile defects is thus apparent in 265 
MHC-ERRB KO mice as early as 6 months (Figure 5E and 5H). 266 
To evaluate calcium handling in these same cardiomyocytes, we measured 267 
calcium release and uptake using Fura2AM fluorescent probes (Figure 6A-F). We found 268 
that dysfunction in calcium handling began as early as 4 months, with Ca2+ release being 269 
significantly decreased (Figure 6A), with a coincident trend in decrease in Ca2+ uptake 270 
(Figure 6D). Curiously, the observed decreases in calcium release and uptake at 4 271 
months (Figure 6A, D) is reversed and becomes a markedly increased calcium release 272 
and uptake at 6 months of age (Figure 6B,E), which persists at 9 months of age (Figure 273 
6C,F).  This increase in calcium release was associated with a time dependent increase 274 
in calcium transients at 6 and 9 months (Figure 6G-I). Taken together, these data 275 
indicate that deregulation of the excitation-contraction coupling apparatus appear in 276 
MHC-ERRB KO mice as early as four months of age, significantly preceding both 277 
cellular contractile defects and echocardiographic abnormalities. 278 
 279 
ESRRβ Protein Localization in Human Heart Failure Sections.  280 
We next sought to determine if ESRRβ localization was affected in human heart failure. 281 
Samples were obtained from native hearts at the time of transplant from patients with 282 
diagnoses of ischemic cardiomyopathy (iCM), hypertrophic cardiomyopathy (HCM), 283 
idiopathic dilated cardiomyopathy (DCM) or postmortem samples of patients who died 284 
suddenly with a diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC), 285 
and compared to control donor hearts. Transmural sections immunostained for ESRRβ 286 
revealed the presence of ESRRβ in the nucleus in all sections with the exception of the 287 
DCM samples (Figure 7A). The pattern of absent ESRRβ staining was seen in 4 of 4 288 
DCM samples, but in zero of 3 control and other cardiomyopathy samples (P<0.01). 289 
Moreover, this localization of ESRRβ was specific, as neither ESRRα (nuclear) (Figure 290 
7B) nor N-cadherin (membrane-bound) revealed any differences in protein distribution 291 
(Figure 7C). Interestingly, in contrast to ESRRα, we did not observe any significant 292 
difference in expression of ESRRβ mRNA in cardiac samples from patients with DCM or 293 
iCM, compared to donor hearts (Figure 7D), indicating that ESRRβ protein expression, 294 
stability, or localization is affected post-transcriptionally. Taken together the data 295 
indicate that ESRRβ protein is undetectable or mislocalized in human DCM. 296 
 297 
Discussion 298 
 299 
The PGC-1s and many of their downstream transcriptional regulators have been 300 
shown to be important in maintaining cardiac metabolic function (5, 39, 40). Members of 301 
the estrogen-related receptor (ESRR) family of orphan receptors have emerged as being 302 
important regulators of cardiac function(46). While bearing significantly homology to the 303 
estrogen receptor, estrogen-related receptors do not bind estrogen and consist of three 304 
members α, β, and γ(15). ESRRα has been studied extensively in the heart and other 305 
metabolic tissues(15), and has been shown to be a key component of the gene 306 
regulatory machinery that regulates mitochondrial biogenesis and function in these 307 
tissue. ESRRγ has been studied much less extensively, but most data indicate a 308 
significant overlap in function between ESRRα and ESRRγ(12). Moreover, germline 309 
deletion of ESRRγ results in post-natal lethality presumably due to impaired cardiac 310 
function(2). ESRRβ appears to have very different role compared to the other family 311 
members, despite their homology. Germline deletion of ESRRβ is embryonic lethal due 312 
to abnormal placental formation during early embryogenesis(30). However, the role of 313 
ESRRβ in cardiac function was unknown. 314 
Here we identify ESRRβ as a key regulator in the development of the dilated 315 
cardiomyopathy. The precise mechanism by which loss of ESRRβ leads to CM remains 316 
uncertain. Our data indicate that impaired calcium homeostasis precedes evidence of 317 
defects in contractility both in cell culture and in intact animals, suggesting that ESRRβ 318 
may regulate calcium handling. The calcium handling phenotype suggested an early 319 
defect in Ca release and uptake, which may account for the alterations in contractility 320 
noted. The later changes that suggested an increase in Ca release and uptake may be 321 
secondary or adaptive, although the mechanisms are still to be elucidated. However, we 322 
did not find that expression of known calcium-handling genes, such as RYR, SERCA2 or 323 
PL, was altered in hearts lacking ESRRβ at the time that calcium-handling defects 324 
appear. It is possible that ESRRβ affects calcium homeostasis via mechanisms other 325 
than regulating gene expression. Such non-genomic mechanisms have been noted for 326 
various nuclear receptors, including estrogen receptor(7, 10, 34). ESRRβ is also well 327 
recognized as a pluripotency factor, able to substitute for classical Yamanaka factors in 328 
certain contexts (13, 14, 23). However, it seems unlikely that cardiomyopathy in the 329 
ESRRβ KO hearts stems from loss of pluripotency, because cardiomyocytes in adult 330 
hearts replicate very little.  331 
Our results suggest that loss of ESRRβ may contribute to the development of 332 
DCM. Nuclear receptors, including ESRRβ, are unique transcription factors in that they 333 
are typically ligand-activated. Nuclear receptors are therefore more easily drugged 334 
targets, providing a potentially amenable translational avenue. An endogenous ligand for 335 
ESRRβ is not known, but various synthetic ligands can activate it (45, 48). It will 336 
therefore be of great interest to test these ligands in models of DCM. 337 
It is interesting that the absence of nuclear ESRRβ was noted in idiopathic DCM 338 
samples, but not in other causes of dilated cardiomyopathy, suggesting that: 1) dilation 339 
of the heart per se does not cause loss of nuclear ESRRβ, and 2) loss of nuclear 340 
ESRRβ may uniquely contribute to the pathogenesis of idiopathic DCM. As noted, at 341 
least a quarter of idiopathic DCM cases are caused by truncating mutations in TTN, the 342 
gene encoding the sarcomeric protein titin. How mutations in a sarcomeric protein 343 
should affect the nuclear localization of a transcription factor is unclear. Evaluation of 344 
ESRRβ location and function in mouse models bearing mutations in ttn, once available, 345 
will therefore be of interest. Therefore, targeting ESRRβ with specific agonist could 346 
provide a new powerful intervention in the treatment of dilated cardiomyopathy.  347 
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Figure Legends 358 
 359 
Figure 1. Identification of ESRRβ in Cardiac metabolism. A.) Schematic of high-360 
throughput qPCR screen. B.) Fold expression of upregulated genes in skeletal muscle of 361 
MCK-PGC-1Tg compared to control littermates. C.) Relative ESRRβ mRNA expression 362 
in various tissues. D.) Relative ESRRβ mRNA expression in Heart, Skeletal Muscle and 363 
Kidney of MHC-ERRBKO and Control mice at 2 months. Data are presented as mean ± 364 
SEM; n = 4-6 per group; * - P < 0.05 compared to control animals. 365 
Figure 2. Cardiac Phenotype of MHC-ERRB KO mice. A.) Kaplan-Meier survival curve 366 
of MHC-ERRBKO animals. B.) Gross heart anatomy of the MHC-ERRBKO animals 367 
compared to control animals. C.) Heart weight normalized to body weight (HW/BW). D.) 368 
Heart weight normalized to tibial length (HW/TL). E.) mRNA expression of heart failure 369 
markers. F.) Masson Trichrome staining. G.) qPCR expression of markers of fibrosis of 370 
MHC-ERRBKO and control animals at 9 to 10 months of age. Data are presented as 371 
mean ± SEM; n = 4-6 per group; * - P < 0.05 compared to control animals. 372 
Figure 3. Non-invasive ECHOs of MHC-ERRBKO. A.) Sample M-mode 373 
echocardiograms from the left ventricle (LV). B.) Anterior wall thickness (AW). C.) Left 374 
ventricular end systolic diameter (LVESD). D.) Left ventricular end diastolic diameter 375 
(LVEDD). E.) Percent fractional shortening (%FS). F.) qPCR expression of OXPHOS 376 
genes. G.) qPCR expression of FAO genes. H.) Complex IV enzymatic activity. I.) 377 
Citrate synthase activity of MHC-ERRBKO and control animals. Data are presented as 378 
mean ± SEM; n = 4-6 per group; * - P < 0.05 compared to control animals. 379 
Figure 4. Normal Function in Younger MHC-ERRBKO Animal. A.) Sample M-mode 380 
echocardiograms from the left ventricle (LV) B.) Left ventricular end systolic diameter 381 
(LVESD). C.) Left ventricular end diastolic diameter (LVEDD). D.) Percent fractional 382 
shortening (%FS) at 4 months. E.) Sample M-mode echocardiograms from the left 383 
ventricle (LV), F.) Left ventricular end systolic diameter (LVESD), G.) Left ventricular end 384 
diastolic diameter (LVEDD). H.) Percent fractional shortening (%FS) at 6 months. I.) 385 
qPCR expression of ESRR isoforms. J.) qPCR expression of OXPHOS genes. K.) 386 
mRNA expression of heart failure markers. Data are presented as mean ± SEM; n = 4-6 387 
per group; * - P < 0.05 compared to control animals. 388 
Figure 5. Decreased contractility in ERRB deleted cardiomyocytes. A-C.) 389 
Sarcomere length (micrometers). D-F.) Maximum contraction length/distance 390 
(micrometers). G-I.) Contraction speed (micrometers/second) of MHC-ERRBKO and 391 
control mice at 4, 6 and 9 months. Data are presented as whisker plots with medians 392 
and min/max values; (N = 3 – 4 animals per group; n = 12 – 20 cells per animals); * - P < 393 
0.05 and ** - P < 0.001 compared to control animals. 394 
Figure 6. Impaired cardiomyocytes calcium homeostasis with ESRRβ deletion. A-395 
C.) Calcium release (Fura2/sec). D-F.) Calcium uptake (Fura2/sec). G-I) Calcium 396 
transients traces (340/380nm) of MHC-ERRBKO and control mice at 4, 6 and 9 months. 397 
Data are presented as whisker plots with medians and min/max values; (N = 3 – 4 398 
animals per group; n = 12 – 20 cells per animals); * - P < 0.05 and ** - P < 0.001 399 
compared to control animals. 400 
Figure 7. ESRRβ localization and expression in human heart samples. A.) 401 
Immunostaining for ESRRβ , B.) ESRRα,  and C.) N-Cadherin in human transmural 402 
sections from arrhythmogenic right ventricular cardiomyopathy (ARVC) (n=3), ischemic 403 
cardiomyopathy (iCM) (n=3), hypertrophic cardiomyopathy (HCM) (n=3), dilated 404 
cardiomyopathy (DCM) (n=4) and control donor (n=3) staining of human hearts. D.) 405 
mRNA expression of ESRR isoforms and PGC-1 in non-failing, ischemic 406 
cardiomyopathy (iCM) (n=13) and dilated cardiomyopathy (DCM) (n=13). * - P < 0.05 407 
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